Ghassan K. Abou-Alfa, MD, discusses the current role for ramucirumab for the treatment of patients with hepatocellular carcinoma in the second-line setting.
Ghassan K. Abou-Alfa, MD, from the Memorial Sloan Kettering Cancer Center, discusses the current role for ramucirumab (Cyramza) for the treatment of patients with hepatocellular carcinoma (HCC) in the second-line setting.
In May 2019, theFDA granted approval to ramucirumab monotherapy for the treatment of patients with HCC who have an alpha-fetoprotein (AFP) level of ≥400 ng/mLand have been previously treated with sorafenib (Nexavar), based on data from the phase III REACH-2 trial. For now, this agent is only applicable to patients with an elevated AFP above 400, says Abou-Alfa, but elevated AFP levels remain a complex piece of information.
New APL Treatment Shows Promise: Higher Survival Rates, Less Toxicity
July 6th 2024ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.
Read More